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Objectives: The aim of this study was to determine the phenotypic and genotypic resistance profiles of
methicillin-resistant Staphylococcus pseudintermedius (MRSP) and to examine the clonal distribution in
Europe and North America.
Methods: A total of 103 MRSP isolates from dogs isolated from several countries in Europe, the USA and Canada
were characterized. Isolates were identified by PCR–restriction fragment length polymorphism (RFLP), antimi-
crobial susceptibility was determined by broth dilution or gradient diffusion, and antimicrobial resistance genes
were detected using a microarray. Genetic diversity was assessed by multilocus sequence typing (MLST), PFGE
and spa typing. Staphylococcal cassette chromosome mec (SCCmec) elements were characterized by multiplex
PCR.
Results: Thirteen different sequence types (STs), 18 PFGE types and 8 spa types were detected. The hybrid
SCCmec element II–III described in a MRSP isolate was present in 75 (72.8%) isolates. The remaining isolates
either had SCCmec type III (n¼2), IV (n¼6), V (n¼14) or VII-241 (n¼4) or were non-typeable (n¼2). The most
common genotypes were ST71(MLST)-J(PFGE)-t02(spa)-II–III(SCCmec) (56.3%) and ST68-C-t06-V (12.6%). In
addition to mecA-mediated b-lactam resistance, isolates showed resistance to trimethoprim [dfr(G)] (90.3%),
gentamicin/kanamycin [aac(6′)-Ie–aph(2′)-Ia] (88.3%), kanamycin [aph(3′)-III] (90.3%), streptomycin [ant(6′)-
Ia] (90.3%), streptothricin (sat4) (90.3%), macrolides and/or lincosamides [erm(B), lnu(A)] (89.3%), fluoroquino-
lones (87.4%), tetracycline [tet(M) and/or tet(K)] (69.9%), chloramphenicol (catpC221) (57.3%) and rifampicin
(1.9%).
Conclusions: Two major clonal MRSP lineages have disseminated in Europe (ST71-J-t02-II–III) and North
America (ST68-C-t06-V). Regardless of their geographical or clonal origin, the isolates displayed resistance to
the major classes of antibiotics used in veterinary medicine and thus infections caused by MRSP isolates rep-
resent a serious therapeutic challenge.
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Introduction
Since its first description in 2005,1 Staphylococcus
pseudintermedius, and not Staphylococcus intermedius, has
been shown to be the species of the Staphylococcus intermedius
group (SIG) that predominantly colonizes dogs and cats.2 – 4 In
addition, S. pseudintermedius is a leading cause of skin infections
and post-operative infections in dogs and cats (reviewed by
Weese and van Duijkeren5) and has zoonotic potential.6 During
the past 5 years, methicillin-resistant S. pseudintermedius
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(MRSP) has posed a therapeutic challenge because of the limited
treatment options.7 – 11 MRSP isolates are characterized by the
presence of the mecA gene, which is located on staphylococcal
cassette chromosome mec (SCCmec) elements and confers
resistance to b-lactam antibiotics. Three SCCmec types
(SCCmec II–III, SCCmec V and SCCmec VII-241) of MRSP have
been completely sequenced.8,12 SCCmec VII-241 (class A mec
complex, ccrA3/B5) is a newly described element8 that is not
related to SCCmec VII from Staphylococcus aureus.13 SCCmec
II–III (class A, ccrA3/B3) consists of a combination of SCCmec
II from Staphylococcus epidermidis and of SCCmec III from
S. aureus and lacks the cadmium resistance operon.8 SCCmec V
is largely homologous to SCCmec type V (5C2&5), previously
named VT or VII from S. aureus.
12,14,15 For identification of
SCCmec elements in MRSP, the typing method of Kondo et al.16
has been adapted in the present study. In addition to resistance
to b-lactams, MRSP isolates display resistance to many classes of
antimicrobial agents such as the aminoglycosides, macrolides,
lincosamides, tetracyclines, trimethoprim, chloramphenicol and
fluoroquinolones.7,8 MRSP colonizes healthy animals17 and
people working with animals,18,19 who may then act as a reser-
voir for MRSP and thereby contribute to the dissemination of
MRSP among the animal and human populations.
Previous studies have shown that specific MRSP genotypes are
predominantly isolated from infection sites in dogs and
cats.7,8,12,20 An association between lineages and geographical
origin has been previously proposed based on the analysis of
small numbers of isolates.4,20 Joint efforts have been combined
to conduct an international multicentre study with the objective
of characterizing MRSP involved in infections or colonizing dogs
in several European countries and North America. Antimicrobial
susceptibility testing, detection of antibiotic resistance genes,
characterization of SCCmec elements and various genotyping
approaches were employed to determine whether specific MRSP
clones are spreading throughout these regions of the world. It is
anticipated that the study will serve as a basis for future molecular
characterization of MRSP isolates in animals and humans.
Materials and methods
Sample collection and identification of
S. pseudintermedius
Bacterial isolates were obtained from diseased and healthy dogs in veter-
inary diagnostic laboratories of different countries (Table 1) and were cul-
tivated on tryptone soy agar containing 5% sheep blood (TSA-SB) (Oxoid
Ltd, Basingstoke, UK) at 378C for 18 h. All isolates had previously been
identified as SIG by means of either a PCR assay21 or the ID 32 STAPH
system (bioMe´rieux, Marcy l’E´toile, France). S. pseudintermedius isolates
were identified using a previously described PCR–restriction fragment
length polymorphism (RFLP) assay based on the MboI digestion pattern
of a PCR-amplified 320 bp internal fragment of the pta gene. MboI restric-
tion of this PCR product generates two restriction fragments of 213 bp
and 107 bp only in S. pseudintermedius since the MboI restriction site is
absent in the other species of the SIG and in S. aureus.22
Multilocus sequence typing (MLST), SmaI-PFGE and spa
typing
Genetic diversity of S. pseudintermedius was determined by MLST of five
genes (16S rDNA, tuf, cpn60, pta and agrD), by SmaI-PFGE and by spa
typing as described previously.4,20,23 PFGE was run for 24 h at 5.6 V/cm
and with pulse time ramping from 2 to 5 s.24 MLST sequences were com-
pared with allele sequences present in the NCBI nucleotide database in
order to determine the allele number. Sequence type (ST) numbers
were assigned using the key table for MLST typing of SIG isolates.4 New
ST numbers are currently assigned by the curator Vincent Perreten
(vincent.perreten@vbi.unibe.ch). The spa typing was done as previously
described,19 but using an additional nested PCR to allow typing of isolates
that were non-typeable with the original protocol. Primers SPspa1F
(5′-CCGCTCTATTTTTAGGTTAATC-3′) and SIspaFlkR1 (5′-
CGTAACAACTCAATGCTACATA-3′) were used in the first PCR step to
amplify the entire spa gene. The internal primers SIspaF
(5′-AACCTGCGCCAAGTTTCGATGAAG-3′) and SIspaR (5′-CGTGG
TTTGCTTTAGCTTCTTGGC-3′) were then used as recently described19 to
amplify and sequence the variable, tandem repeat region (X-region) of
the spa gene. New types were assigned by the curator of the spa data-
base, Arshnee Moodley (asm@life.ku.dk).
Determination of antibiotic resistance profile
MICs of most of the antimicrobial agents tested were determined by
broth microdilution according to the recommendations of the CLSI25
using microdilution panels (VetMICTM; National Veterinary Institute,
Uppsala, Sweden) with dried and stabilized antimicrobial agents. Deter-
mination of the MICs of rifampicin, mupirocin and the combination qui-
nupristin/dalfopristin was conducted using gradient diffusion strips
according to the instructions of the producer (Etestw; AB Biodisk, Solna,
Sweden). Inducible clindamycin resistance was tested using the
D-test.26 S. aureus ATCC 29213 and S. aureus ATCC 25923 served as
quality control strains. PBP2a was detected with the penicillin binding
protein PBP2a latex agglutination test (Oxoid Ltd) in accordance with
the supplier’s instructions.
The MIC breakpoints for the classification of the isolates as resistant
were those recommended in CLSI documents M100-S19 and
M31-A3.26,27 The resistance breakpoint of ≥0.5 mg/L for oxacillin was
used as recommended by Bemis et al.28 and has recently been approved
by the CLSI subcommittee on Veterinary Antimicrobial Susceptibility
Testing (http://data.memberclicks.com/site/aavld/Letter to the Edi-
tor.pdf). Despite the lack of CLSI-approved interpretive criteria for strepto-
mycin, isolates for which the MIC was ≥32 mg/L were tentatively
considered as streptomycin resistant.
Antibiotic resistance genes were detected using a microarray capable
of detecting .90 resistance genes known to occur in Gram-positive
bacteria.29 The custom ArrayTubes were manufactured by CLONDIAG
Chip Technologies (Jena, Germany) and are distributed by Identibac
(Weybridge, UK). The presence of the bifunctional gene aac(6′)-Ie–
aph(2′)-Ia was demonstrated by PCR using one forward primer specific
to aac(6′)-Ie and one reverse primer specific to aph(2′)-Ia.30
Characterization of SCCmec
The presence of SCCmec types I–VI was determined by multiplex PCR
assays.16 In multiplex PCR 1, the presence of mecA was confirmed and
the ccr gene complex was determined. The PCR products for the internal
part of the ccrC gene were sequenced to identify the ccrC type. In multi-
plex PCR 2, the type of mec complex was assigned. For detection of the
novel recombinase gene complex ccrA3/B5 present in SCCmec type
VII-241 cassettes,9 primers 5′-GCCAAAATTTCTTTCGAGACC-3′ and 5′-TAC
GTGCGAGTCGATTTGTT-3′ were used. The presence of SCCmec II–III was
demonstrated by the absence of the cadmium resistance operon
(present in SCCmec III and absent in SCCmec II and SCCmec II–III)8
using a multiplex PCR containing primers sccmecIII-F4 (5′-AACAGC
CATGACAAGCAC-3′) and sccmecIII-R3 (5′-TAATGCCCATCATTTCAC-3′) that
anneal in the flanking regions of the cadmium resistance operon and
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Table 1. Origin, year of isolation and clinical condition of dogs infected with MRSP of different MLST groups
Clinical condition N Year of isolation n Region (n) MLST (n)
Healthya 22 2004 4 ON (4) ST58 (3), ST113
2006 1 S (1) ST69
2007 9 D (9) ST71 (9)
2008 8 D (8) ST71 (8)
Pyoderma 25 2004 1 D (1) ST5
2006 10 TN (10) ST68 (10)
2007 8 NL (5), CH (2), I (1) ST71 (6), ST106, ST114
2008 6 CA (3), D (2), DK (1) ST71 (3), ST68, ST112, ST116
Wound infections after surgery 22 2005 1 CH (1) ST71
2006 4 CH (3), S (1) ST71 (4)
2007 12 CH (9), S (1), NL (2) ST71 (12)
2008 5 CH (4), NC (1) ST71 (4), ST68
Wound infections 5 2007 2 I (1), NL (1) ST71 (2)
2008 2 CH (1), D (1) ST71 (2)
2009 1 DK (1) ST71
Otitis externa 8 2004 1 CH (1) ST73
2006 1 CH (1) ST71
2007 2 CH (2) ST71 (2)
2008 4 D (1), DK (1), CA (1), ON (1) ST71 (2), ST111, ST106
Urinary tract infection 6 2006 2 I (2) ST71 (2)
2008 4 CH (1), ON (3) ST71 (3), ST68
Arthritis/synovitis 5 2007 5 NL (3), CH (1), I (1) ST71 (5)
Respiratory tract infection 2 2005 1 D (1) ST71
2006 1 I (1) ST71
Encephalitis 1 2006 1 I (1) ST71
Gingivitis 1 2006 1 CH (1) ST71
Hepatitis 1 2007 1 I (1) ST71
Peritonitis 1 2007 1 NL (1) ST71
Septicaemia 1 2007 1 I (1) ST71
Unknown 3 2008 3 D (2), CA (1) ST71 (2), ST115
Total per year 103 2004 6 CH (1), D (1), ON (4) ST58 (3), ST5, ST73, ST113
2005 2 CH (1), D (1) ST71 (2)
2006 21 CH (5), I (4), TN (10), S (2) ST68 (10), ST71 (10), ST69
2007 41 CH (14), D (9), NL (12), I (5), S (1) ST71 (39), ST106, ST114
2008 32 CH (6), D (14), CA (5), ON (4), DK (2),
NC (1)
ST71 (24), ST68 (3), ST106, ST111, ST112,
ST115, ST116
2009 1 DK (1) ST71
Total 103 2004–09 103 CH (27), D (25), I (9), DK (3), CA (5),
NC (1), NL (12), ON (8), S (3), TN (10)
ST71 (76), ST68 (13), ST58 (3), ST106 (2),
ST5, ST69, ST73, ST111, ST112, ST113,
ST114, ST115, ST116
N, number of animals; n, number of MRSP isolates.
European countries and North American regions (USA and Canada): CA, California; CH, Switzerland; D, Germany; DK, Denmark; I, Italy; NC, North
Carolina; NL, the Netherlands; ON, Ontario; S, Sweden; TN, Tennessee.
aNose, mouth or perineum colonization.
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Table 2. Genetic characteristics and distribution of antibiotic resistance in MRSP from different countries
Sequence type and PFGE
profile Antibiotic resistance properties and genes
MLST spa PFGE OXA PEN GEN/KAN KAN STR STH ML TMP LIN TET CHL CIP RIF
SCCmec
type
Origin (no. of
isolates)
Total no. of
isolates
ST71 t02 J mecA blaZ aac(6′)-Ie–aph(2 ′)-Ia aph(3′)-III ant(6 ′)-Ia sat4 erm(B) dfr(G) tet(K) catpC221 + + II–III I (1) 1
ST71 t02 J (34), K (1), P (1) mecA blaZ aac(6′)-Ie–aph(2 ′)-Ia aph(3′)-III ant(6 ′)-Ia sat4 erm(B) dfr(G) tet(K) catpC221 + II–III CH (9), D (17), I (8),
NL (1), ON (1)
36
ST71 t05 J mecA blaZ aac(6′)-Ie–aph(2 ′)-Ia aph(3′)-III ant(6 ′)-Ia sat4 erm(B) dfr(G) tet(K) catpC221 + II–III D (1) 1
ST71 t06 M mecA blaZ aac(6′)-Ie–aph(2 ′)-Ia aph(3′)-III ant(6 ′)-Ia sat4 erm(B) dfr(G) tet(K) catpC221 + + II–III NL (1) 1
ST71 t06 J mecA blaZ aac(6′)-Ie–aph(2 ′)-Ia aph(3′)-III ant(6 ′)-Ia sat4 erm(B) dfr(G) tet(K) catpC221 + II–III CH (1) 1
ST71 t02 J (10), K(1) mecA blaZ aac(6′)-Ie–aph(2 ′)-Ia aph(3′)-III ant(6 ′)-Ia sat4 erm(B) dfr(G) tet(K) + II–III CH (7), D (2), NL (2) 11
ST71 t02 J (9), G (2), H (1),
L (1), M (1)
mecA blaZ aac(6′)-Ie–aph(2 ′)-Ia aph(3′)-III ant(6 ′)-Ia sat4 erm(B) dfr(G) catpC221 + II–III CH (9), S (1), NL (4) 14
ST71 t03 J mecA blaZ aac(6′)-Ie–aph(2 ′)-Ia aph(3′)-III ant(6 ′)-Ia sat4 erm(B) dfr(G) catpC221 + II–III NL (1) 1
ST71 t02 J (2), G (1), R (1) mecA blaZ aac(6′)-Ie–aph(2 ′)-Ia aph(3′)-III ant(6 ′)-Ia sat4 erm(B) dfr(G) + II–III D (1), CA (2), NL (1) 4
ST71 t02 H mecA blaZ aac(6′)-Ie–aph(2 ′)-Ia aph(3′)-III ant(6 ′)-Ia sat4 erm(B) dfr(G) + IV DK (1) 1
ST71 t03 J mecA blaZ aac(6′)-Ie–aph(2 ′)-Ia aph(3′)-III ant(6 ′)-Ia sat4 erm(B) dfr(G) + II–III D (1) 1
ST71 t06 J (2) mecA blaZ aac(6′)-Ie–aph(2 ′)-Ia aph(3′)-III ant(6 ′)-Ia sat4 erm(B) dfr(G) + II–III ON (2) 2
ST71 t02 J mecA blaZ aac(6′)-Ie–aph(2 ′)-Ia aph(3′)-III ant(6 ′)-Ia sat4 dfr(G) tet(K) catpC221 + II–III D (1) 1
ST71 t02 J mecA blaZ aac(6′)-Ie–aph(2 ′)-Ia dfr(G) catpC221 + II–III S (1) 1
ST68 t06 C (6) mecA blaZ aac(6′)-Ie–aph(2 ′)-Ia aph(3′)-III ant(6 ′)-Ia sat4 erm(B) dfr(G) tet(M) + V TN (6) 6
ST68 t06 C (6) mecA blaZ aac(6′)-Ie–aph(2 ′)-Ia aph(3′)-III ant(6 ′)-Ia sat4 erm(B) dfr(G) lnu(A) tet(M) + V TN (3), CA (1),
NC (1), ON (1)
6
ST68 t06 C mecA blaZ aac(6′)-Ie–aph(2 ′)-Ia tet(M) + V TN (1) 1
ST5 t05 S mecA blaZ aac(6′)-Ie–aph(2 ′)-Ia dfr(G) tet(K) tet(M) A1a D (1) 1
ST58 t06 F (3) mecA blaZ VII-241 ON (3) 3
ST69 t07 A mecA blaZ aph(3′)-III ant(6 ′)-Ia sat4 erm(B) catpC221 B2
a S (1) 1
ST73 t24 S mecA tet(M) + VII-241 CH (1) 1
ST106 t02 U mecA blaZ aph(3′)-III ant(6 ′)-Ia sat4 erm(B) dfr(G) tet(M) IV NL (1) 1
ST106 t02 ND mecA blaZ dfr(G) tet(M) III DK (1) 1
ST111 t05 U mecA blaZ aph(3′)-III ant(6 ′)-Ia sat4 erm(B) dfr(G) tet(M) IV CA (1) 1
ST112 t25 Q mecA blaZ IV CA (1) 1
ST113 t06 D mecA blaZ aph(3′)-III ant(6 ′)-Ia sat4 erm(B) IV ON (1) 1
ST114 t06 V mecA blaZ tet(M) III NL (1) 1
ST115 t21 E mecA blaZ aac(6′)-Ie–aph(2 ′)-Ia aph(3′)-III ant(6 ′)-Ia sat4 erm(B) dfr(G) tet(K) tet(M) catpC221 + V D (1) 1
ST116 t02 W mecA blaZ aph(3′)-III ant(6 ′)-Ia sat4 erm(B) IV DK (1) 1
Total 103 102 91 93 93 93 92 93 6 54 20 59 90 2 103
Percentage 100 99 88.3 90.3 90.3 90.3 89.3 90.3 5.8 52.4 19.4 57.3 87.4 1.9
ND, not determined.
Antibiotics: OXA, oxacillin; PEN, penicillin; GEN, gentamicin; STR, streptomycin; KAN, kanamycin; CHL, chloramphenicol; TMP, trimethoprim; ML, macrolides/lincosamides; LIN, lincosa-
mides; TET, tetracycline; STH, streptothricin; CIP, ciprofloxacin; RIF, rifampicin.
European countries and North American regions (USA and Canada): CA, California; CH, Switzerland; D, Germany; DK, Denmark; I, Italy; NC, North Carolina; NL, the Netherlands; ON,
Ontario; S, Sweden; TN, Tennessee.
+, resistant to the tested drug, but the resistance mechanism was not determined; +, intermediate resistance; blank spaces indicate no resistance.
aA1 and B2 designations were used for non-typeable SCCmec: A1 belongs to mec class A with ccrA1/B1; and B2 belongs to mec class B with ccrA2/B2 and ccrA4/B4.
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primer scc241-F6 (5′-AAGACTTAGCAGGAAAACGC-3′) that anneals within
the cadB gene. This multiplex PCR generated either a 1118 bp fragment
in the presence of the cadmium resistance operon or a 831 bp fragment
in the absence of the operon. PCRs were performed using an annealing
temperature of 548C and an extension time of 1 min.
Results
Identification of and clonal relationship between MRSP
Eighty-one isolates were from animals with clinical symptoms
and 22 isolates colonized healthy animals (Table 1). A pta PCR
product of 320 bp was amplified from all isolates examined,
and all PCR products contained a single MboI site (data not
shown), indicative of S. pseudintermedius.22
The 103 MRSP isolates were assigned to 13 different STs, 18
PFGE types and 8 spa types (Table 2). The majority of the inves-
tigated MRSP isolates belonged to the two STs ST71 (n¼76,
73.8%) and ST68 (n¼13, 12.6%), the two PFGE types J (n¼64,
62.1%) and C (n¼13, 12.6%) and the two spa types t02
(n¼72; 69.9%) and t06 (n¼22; 21.4%) (Table 2). All isolates
assigned to ST68 displayed the same PFGE profile C and had
spa type t06 [ST68(MLST)-C(PFGE)-t06(spa)]. Sixty-four (84.2%)
of the 76 isolates representing ST71 displayed the same PFGE
pattern J. They belonged mainly to spa type t02 (58/76)
(ST71-J-t02) and rarely to spa types t06 (3/76), t03 (2/76) and
t05 (1/76). Among the remaining 12 ST71 isolates (15.8%), 7
unique PFGE profiles were observed. Eleven of these isolates
belonged to spa type t02, while the remaining isolate belonged
to t06 (Table 2). Moreover, spa type t02 was also detected
among MRSP isolates that were assigned to ST106 and ST116.
These two STs were not closely related to ST71 and clustered
in two separate branches of the eBURST diagram (Figure 1).
Three isolates (2.9%) belonged to ST58-F-t06 (Table 2). Other
genotypes, including ST5, ST69, ST73 and ST111–ST116, were
represented by single isolates; they also had distinct PFGE pro-
files, except ST5 and ST73 that share the same profile (Table 2).
SCCmec distribution in MRSP
SCCmec typing revealed the presence of five SCCmec types
(II–III, III, IV, V and VII-241) as well as two non-typeable
cassettes: one harboured ccrA1/B1 with class A mec complex
(A1); and the other harboured the recombinase genes ccrA2/B2
and ccrA4/B4 with class B mec complex (B2) (Table 2). SCCmec
II–III was most frequently seen (75/103) and mainly associated
with MRSP isolates of ST71. SCCmec III was detected in two iso-
lates assigned to ST106 and ST114, respectively. SCCmec V was
found in all ST68 isolates and ST115. SCCmec IV was associated
with six different STs (71, 106, 111, 112, 113 and 116), while
SCCmec VII-241 was identified in ST58 and ST73 (Table 2). All iso-
lates of the clonal lineage ST68 and the ST115 isolate harboured
ccrC2 and ccrC8 and thus very likely belonged to type V (5C2&5).
The two non-typeable SCCmec elements were detected in two
isolates that belonged to ST5 and ST69, respectively (Table 2).
Antibiotic resistance profile
All isolates contained mecA and 102 carried the b-lactamase
gene blaZ (Tables 2 and 3). All the isolates were considered to
be resistant to oxacillin using the recently revised CLSI
breakpoints applicable to S. pseudintermedius. Tetracycline resist-
ance was attributed to either tet(M) or tet(K), or both genes in
two isolates. Resistance to macrolides and lincosamides was
due to the methylase gene erm(B). Two isolates containing
erm(B) displayed inducible resistance to clindamycin, otherwise
clindamycin resistance was constitutively expressed. The lincosa-
mide nucleotidyltransferase gene lnu(A) that confers resistance
only to lincosamides, but not to macrolides, was only detected
in six isolates that also contained erm(B). The chloramphenicol
acetyltransferase gene catpC221 was detected in chloramphenicol-
resistant isolates and the dihydrofolate reductase gene dfr(G)
was found in the trimethoprim-resistant isolates. The streptothri-
cin acetyltransferase gene sat4 was detected in 93 (90.3%) iso-
lates. Resistance to aminoglycosides was associated with the
adenyltransferase gene ant(6′)-Ia (streptomycin resistance), the
phosphotransferase gene aph(3′)-III (kanamycin resistance) or
the bifunctional acetyltransferase/phosphotransferase gene
aac(6′)-Ie–aph(2′)-Ia (gentamicin and kanamycin resistance).31,32
Nineteen isolates containing the aac(6′)-Ie–aph(2′)-Ia gene
displayed MICs of gentamicin of either 4 or 8 mg/L that classify
the respective isolates as either borderline susceptible or inter-
mediate according to the currently available CLSI breakpoints
for staphylococci.27
Using the human breakpoints for resistance to ciprofloxacin
and veterinary-specific breakpoints for resistance to enrofloxacin
(both at ≥4 mg/L),26,27 90 isolates were classified as resistant to
ciprofloxacin and 87 isolates as resistant to enrofloxacin. While
only a single isolate for which the MIC was 2 mg/L was classified
as intermediate to ciprofloxacin, five isolates for which the MIC
was 1 or 2 mg/L were classified as intermediate to enrofloxacin
(Table 3). Two isolates displayed high MICs of ≥64 mg/L rifampi-
cin. The resistance mechanism to fluoroquinolones or rifampicin
was not determined in the present study.
Geographical and clinical distribution of MRSP clones
The multiresistant clonal lineage ST71(MLST)-J(PFGE)-t02(spa)-
II–III(SCCmec) was widespread in several European countries,
but was detected only sporadically among dogs from North
America, namely in California and Ontario. In North America,
ST68-C-t06-V was the predominant lineage found in several
regions (Tennessee, California, North Carolina and Ontario). This
North American clonal lineage contained virtually the same
resistance genes as the European clonal lineage ST71, with the
exception of tet(M), which replaced tet(K), the absence of
catpC221 and an additional lincosamide resistance gene lnu(A)
in some ST68 isolates. MRSP isolates belonging to unique STs,
such as ST69, ST113, ST114 and ST116, originated from different
countries (Table 2 and Figure 1). They also harboured less anti-
biotic resistance genes than isolates belonging to the predomi-
nant ST71 and ST68 lineages (Table 2). Genetic diversity was
more frequent among isolates from skin infection sites than
among isolates from surgical infection sites, which all belonged
to ST71. ST71 was also the predominant sequence type
(77.3%) among MRSP isolates from healthy dogs (Table 1).
Discussion
Two major clonal lineages characterized by resistance to nine
therapeutically important classes of antimicrobial agents were
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Figure 1. Population snapshot of S. pseudintermedius. Clusters of related STs within the entire S. pseudintermedius MLST database are displayed as a single eBURST diagram by setting
the group definition to zero of five shared alleles. Clusters of linked isolates correspond to clonal complexes. The STs found in the present study are marked by geometric symbols that
also indicate geographical origin: open circles, exclusive to Europe; open squares, exclusive to North America; and open triangles, found in Europe and North America.
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Table 3. MICs of 21 antimicrobial agents for 103 MRSP and distribution of antibiotic resistance genes
MIC (mg/L)
Antimicrobial
Resistance
breakpoint
(mg/L)
Range
tested ,0.03 0.03 0.06 0.12 0.25 0.5 1 2 4 ≥8 ≥16 ≥32 ≥64 ≥128 ≥256
Number of
resistant
isolates
(%) Resistance genes (n)
Percentage
of isolates
with
resistance
genes
Cefoxitin NA 0.12–16 1 4 13 18 30 23 9 5 — mecA (103) 100
Cefalotin ≥32 0.06–8 1 5 7 3 2 4 5 76 — mecA (103) 100
Oxacillin with
2% NaCl
≥0.5 0.12–16 1 4 5 2 2 89 103 (100) mecA (103) 100
Penicillin ≥0.25 0.06–4 1 102 103 (100) mecA (103); blaZ (102) 100; 99.0
Chloramphenicol ≥32 4–64 8 36 6 51 2 59 (57.3) catpC221 (59) 57.3
Ciprofloxacin ≥4 0.06–4 1 8 3 1 90 90 (87.4) ND ND
Clindamycin ≥4 0.25–32 9 3 1 90 92a (89.3) erm(B) (92); lnu(A) (6) 89.3; 5.8
Enrofloxacin ≥4 0.12–16 6 3 2 3 2 3 24 18 42 87 (84.5) ND ND
Erythromycin ≥8 0.25–32 11 92 92 (89.3) erm(B) (92) 89.3
Fusidic acid NA 0.06–8 3 38 43 11 6 1 1
Gentamicin ≥16 0.5–64 11 1 8 11 9 27 32 4 72 (69.9) aac(6′)-Ie–aph(2′)-Ia
(91)
88.3
Kanamycin ≥64 0.25–32 4 2 1 96 96 (93.2) aph(3′)-III (93) 90.3
Linezolid NA 0.12–16 15 84 4 —
Mupirocin NA 0.06–256 77 24 1 1 —
Quinupristin/
dalfopristin
≥4 0.06–32 1 9 41 52 0 (0)
Rifampicin ≥4 0.03–32 101 2 2 (1.9) ND ND
Streptomycin ≥32 2–128 1 8 1 93 93 (90.3) ant(6′)-Ia (93) 90.3
Streptothricin NA ND ND sat4 (93) 90.3
Tetracycline ≥16 0.5–64 31 36 35 1 72 (69.9) tet(M) (18); tet(K) (52); 17.5; 50.5;
tet(M) and tet(K) (2) 1.9
(total: 72) (total: 69.9)
Trimethoprim ≥16 0.5–32 6 4 93 93 (90.3) dfr(G) (93) 90.3
Vancomycin ≥32 0.12–16 3 93 7 0 (0)
NA, not available; ND, not determined.
The MIC breakpoints determining resistance were those recommended for staphylococci in CLSI documents M100-S1926 and M31-A3.27 The resistance breakpoint of ≥0.5 mg/L for
oxacillin was used as approved by the CLSI subcommittee on Veterinary Antimicrobial Susceptibility Testing. The resistance breakpoint of ≥32 mg/L was tentatively used for
streptomycin.
aTwo isolates harbouring erm(B) displayed inducible resistance to clindamycin.
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found to be prevalent in Europe (ST71-J-t02-II–III) and North
America (ST68-C-t06-V) (Table 2). Different antibiotic resistance
gene profiles were present among isolates belonging to ST71
suggesting independent acquisition or loss of resistance genes,
such as tet(K), catpC221 or erm(B). Borderline susceptibility to gen-
tamicin was observed in some MRSP isolates that contained the
bifunctional aminoglycoside resistance gene aac(6′)-Ie–
aph(2′)-Ia. Similarly, lower MICs have already been observed
for staphylococci from horses that expressed aac(6′)-Ie–
aph(2′)-Ia.33 In this regard, it should be noted that clinical break-
points may reflect more than just the presence or absence of
resistance genes and that the observed MICs may also depend
on the expression level and/or the copy number of a resistance
gene present.34 Although inducible clindamycin resistance
appeared to be more frequent in methicillin-resistant
Staphylococcus aureus (MRSA) than in MRSP,35 two MRSP isolates
were found to have the resistance gene erm(B) and inducible
resistance to clindamycin. Since erm(B) gene prevalence is very
high in MRSP, it is recommended that the D-test be performed
for all erythromycin-resistant isolates that are not simul-
taneously resistant to clindamycin. All but one of the isolates
containing the aminoglycoside resistance genes aph(3′)-III and
ant(6′)-Ia, as well as the streptothricin resistance gene sat4,
also harboured the erm(B) gene, suggesting the presence of
Tn5405-like elements that have already been reported to be
present in S. pseudintermedius from dogs.36 In these elements,
erm(B) was linked to the resistance gene cluster ant(6′)-Ia–
sat4–aph(3′)-III.36
MLST followed by eBURST clustering has been shown to be an
excellent tool to study bacterial population structures and global
epidemiology. To investigate the evolution of MRSP, eBURST clus-
tering of all S. pseudintermedius STs revealed one large clonal
complex, with ST28 as the founder and 15 sub-founders
(Figure 1). This clustering pattern might suggest a high recombi-
nation rate over point mutations within this species;37,38
however, recombination and mutation rates have not yet been
studied in S. pseudintermedius. In addition, the current
S. pseudintermedius MLST scheme needs optimization. Most
MLST schemes have seven or more loci and none includes 16S
rDNA.
Initially, only 93 (90.3%) of the 103 isolates were spa typeable
using the method described by Moodley et al.20 The spa products
of non-typeable isolates could not be sequenced due to the pres-
ence of multiple bands. This was later found to be related to the
presence of two adjacent spa genes, with 79% nucleotide
sequence identity (data not shown). This second spa gene has
three IgG-binding domains and a partial deletion of the
X-region. The biological significance of this gene duplication in
MRSP is unclear, but by using the nested PCR approach described
in the present study, only the spa gene containing the complete
X-region is amplified. The results of the present study indicated
that the same spa type can be found in unrelated STs and
PFGE types. This has been reported in MRSA and hypothesized
to be a result of convergent evolution or genetic recombina-
tion.39,40 PFGE showed good correlation with MLST and was
more discriminatory than spa typing for isolates belonging to
the same ST lineage. Nevertheless, 58 (56.3%) of all MRSP iso-
lates shared the same ST71-J-t02-II–III profile and the same
antibiotic resistance genes indicating that a predominant MRSP
clone is spreading in the dog population. MRSP ST71 isolates
containing SCCmec type II–III have also been detected in dogs
in Canada and the USA and have been recently reported in
Hong Kong,19 emphasizing the global spread of MRSP ST71.
Further surveillance and genetic characterization of the newly
emerging STs of MRSP will facilitate comparison of their patho-
genic potential with the established clonal lineages ST68 and
ST71.
It is clear that MRSP is a nosocomial pathogen in veterinary
settings in a similar fashion to hospital-acquired MRSA lineages
in human medicine.41 The dissemination of such multidrug-
resistant staphylococci among dogs is of concern as the
options for therapy are limited. People working with animals
have become carriers of MRSP.18,19 Thus, veterinary personnel
could transfer the pathogen from animal to animal, which
further emphasizes its veterinary nosocomial potential. As
cases of human infections with S. pseudintermedius have been
reported,5,6 including MRSP infections,42,43 the appropriateness
of veterinary use of ‘antibiotics of last resort’, like vancomycin,
linezolid and the combination quinupristin/dalfopristin, that are
used for the treatment of methicillin-resistant staphylococci in
human medicine, is questionable.
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